Ignite Creation Date:
2024-05-06 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04707820
Status:
UNKNOWN
Last Update Posted:
2021-01-13
First Post:
2020-12-29
Brief Title:
Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection
Sponsor:
University Hospital Rouen
Organization:
University Hospital Rouen
Study Overview
Official Title:
Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection
Status:
UNKNOWN
Status Verified Date:
2020-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ImmuCoV
Brief Summary:
The SARS-CoV-2 COVID-19 infection is causing a global pandemic and a major health crisis in France
Immunity is the bodys ability to defend itself against infectious agents such as viruses The progressive acquisition by a large part of the population of immunity to defend itself against the COVID-19 virus is one of the main mechanisms by which a resolution of this pandemic is hoped for Recovery from infection and protection from the virus is likely to depend on the development of antibodies proteins produced by the body to neutralize infectious agents and T-cells a type of white blood cell in the immune system that can stop the virus from multiplying and killing it
To date the way and speed at which the T-lymphocytes active against the virus appear are not known The development of biological tests to detect T-cells active against the virus in the blood of infected patients is therefore necessary
In this context we propose you to participate in a study that will study the immune systems response against the sars-CoV-2 virus during and after COVID-19 infection
Immunity is the bodys ability to defend itself against infectious agents such as viruses The progressive acquisition by a large part of the population of immunity to defend itself against the COVID-19 virus is one of the main mechanisms by which a resolution of this pandemic is hoped for Recovery from infection and protection from the virus is likely to depend on the development of antibodies proteins produced by the body to neutralize infectious agents and T-cells a type of white blood cell in the immune system that can stop the virus from multiplying and killing it
To date the way and speed at which the T-lymphocytes active against the virus appear are not known The development of biological tests to detect T-cells active against the virus in the blood of infected patients is therefore necessary
In this context we propose you to participate in a study that will study the immune systems response against the sars-CoV-2 virus during and after COVID-19 infection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None